⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MLTX News
MoonLake Immunotherapeutics Class A Ordinary Shares
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
MLTX
Pomerantz LLP Advises Shareholders of Class Action Involving MoonLake Immunotherapeutics – MLTX
accessnewswire.com
MLTX
MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab
globenewswire.com
MLTX
Securities Lawsuit Alert: MoonLake Immunotherapeutics (MLTX) - Contact Levi & Korsinsky Before December 15, 2025
accessnewswire.com
MLTX
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman
accessnewswire.com
MLTX
Pomerantz LLP Alerts Shareholders to Investor Suit Filed Against MoonLake Immunotherapeutics – MLTX
accessnewswire.com
MLTX
Investor Alert: Deadline Approaching to Join MoonLake Immunotherapeutics (MLTX) Class Action - Contact Levi & Korsinsky
accessnewswire.com
MLTX
MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
prnewswire.com
MLTX
MLTX COURT NEWS: MoonLake Immunotherapeutics Investor Deadline December 15 - Investors Notified to Contact BFA Law to Potentially Recover Losses
accessnewswire.com
MLTX
Class Action Alert: Levi & Korsinsky Reminds MoonLake (MLTX) Investors of December 15, 2025 Deadline
accessnewswire.com
MLTX